REGN9220 / Regeneron - LARVOL DELTA

REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) (clinicaltrials.gov) - P1/2 | N=36 | Not yet recruiting | Sponsor: Regeneron Pharmaceuticals

New P1/2 trial • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology